6079398
Last Update Posted: 2026-02-20
Recruiting
All Genders accepted | 0 Years-2 Years |
72 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Eligibility
Relevant conditions:
Achondroplasia
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Ascendis Registry Inquiries
asnd_registryinquiries@ascendispharma.com
+45 61242484
Data sourced from ClinicalTrials.gov